Shares of Jazz Pharmaceuticals JAZZ were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 9.50% year over year to $4.00, which missed the estimate of $4.20.
Revenue of $665,517,000 higher by 14.40% year over year, which beat the estimate of $639,550,000.
Outlook
Jazz Pharma Sees FY21 Sales $2.55B-$2.7B vs $2.56B Estimate, Adj. EPS $15.65-$16.85 vs $16.78 Estimate
Conference Call Details
Date: Feb 23, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/7h5iem3y
Price Action
52-week high: $172.67
Company's 52-week low was at $86.88
Price action over last quarter: Up 5.93%
Company Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
